RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Financial documents

Financial reports

2022Press releaseReportPresentationWebcastTranscriptXBRL

20 Oct 2022

Interim report January-September 2022

19 Jul 2022

Interim report January-June 2022

21 Apr 2022

Interim report January-March 2022

Coffee and notepad


Sign up to receive updates on the latest company news and filings

Choose type

Thank you. You will get an e-mail message to activate your subscription.
Investor Relations

Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709 298 269

Email: klaus.sindahl@hansabiopharma.com